You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

HIV and Hepatitis.com Coverage of the
45th Annual Meeting of the European
Association for the Study of the Liver (EASL 2010)

April 14 - 18, 2010, Vienna, Austria
HCV Therapeutic Vaccine GI-5005 Improves Rate of Sustained Response to Interferon-based Therapy for Hepatitis C

SUMMARY: Genotype 1 chronic hepatitis C patients who used GI-5005, GlobeImmune's investigational hepatitis C virus (HCV) therapeutic vaccine, along with pegylated interferon plus ribavirin were more likely to achieve sustained virological response and reductions in ALT than those treated with standard-of-care therapy alone, according to 3 studies presented this month at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) in Vienna. GI-5005 improved sustained response rates in people with all IL-28 genotypes, but the effect appeared to be greatest in those with an unfavorable gene pattern associated with poor interferon response.

By Liz Highleyman

Below is an excerpt from a GlobeImmune press release describing final results from a Phase 2b study of GI-5005 in previously untreated chronic hepatitis C patients.

GlobeImmune GI-5005 HCV Product Candidate Improves
Sustained Virologic Response by 10 Percent, Demonstrating
Potential to Be First Therapeutic Vaccine for HCV

Final Phase 2b Data for GI-5005 in Treatment-Naive Patients Presented at 45th Annual Meeting of the European Association for the Study of the Liver

Louisville, CO -- April 15, 2010 -- GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, the Company's investigational Tarmogen product candidate, demonstrating its potential to be the first successful therapeutic vaccine for chronic hepatitis C virus (HCV) infection. The data show that GI-5005 increased the sustained virologic response (SVR) in genotype 1 interferon-naive patients to 58 percent when used in combination with standard of care (SOC), pegylated interferon-a2a plus ribavirin, versus 48 percent for patients receiving SOC alone. The study also demonstrated that adding GI-5005 to SOC results in an improvement in normalization of alanine aminotransferase (ALT) levels and suggests an improvement in liver biopsies, both markers used to assess liver damage.

Ira M. Jacobson, MD, the Vincent Astor Distinguished Professor of Medicine at NewYork-Presbyterian/Weill Cornell Medical Center, and John G. McHutchison, MD, Associate Director of the Duke Clinical Research Institute at Duke University Medical Center, presented the data today at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

"This is the first clinical study to demonstrate that a therapeutic vaccine can be used for patients with chronic hepatitis C infection," said Dr. Jacobson. "With its novel mode of action and apparent safety profile, the GI-5005 therapeutic vaccine could have an important impact on the treatment of this disease."

The Phase 2b study compared GI-5005 plus SOC versus SOC alone in 140 patients with chronic genotype 1 hepatitis C infection who were either treatment-naive or prior non-responders to SOC. On an intent-to-treat basis (patients having received at least one dose of combination therapy), treatment-naive patients receiving GI-5005 plus SOC as a triple therapy had an SVR rate of 58 percent, compared to an SVR rate of 48 percent in treatment-naive patients receiving SOC alone, a relative improvement of 21 percent. GI-5005 triple therapy demonstrated a 67 percent relative improvement in the proportion of patients achieving normalization of ALT levels on therapy. ALT is a marker of liver injury that is used to follow liver function in HCV patients. In addition, a trend toward an improvement in biopsy necroinflammatory scores was seen with a 39 percent relative improvement compared to those receiving SOC alone. The most common adverse events associated with GI-5005 were injection site reactions that were generally mild and transient in nature. Importantly, GI-5005 did not increase the discontinuation rates due to adverse events when added to standard of care (GI-5005 + SOC - 13.2 percent vs. SOC alone -- 12.3 percent).

"These data show that adding GI-5005 to standard of care may give patients a clinically important advantage without added toxicity," said David Apelian, MD, Ph.D., Chief Medical Officer at GlobeImmune. "We believe that this is an important medical breakthrough in the treatment of hepatitis C, and it may have implications for the development of treatments for other chronic viral infections."

Pharmacogenomic data demonstrating a correlation between GI-5005 treatment effect and polymorphisms in the human IL-28 B gene will also be presented at the EASL meeting on Saturday, April 17 by Dr. McHutchison.

Tarmogens are whole, heat-killed recombinant S. cerevisiae yeast that are engineered to express one or more disease-related proteins. GlobeImmune's GI-5005 Tarmogen is a therapeutic vaccine product candidate that contains conserved HCV structural proteins and is designed to generate an HCV specific T-cell response.

About GlobeImmune

GlobeImmune, Inc. is a private company developing active immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T-cells that locate and eliminate cancer cells and/or virally-infected cells. The company's lead product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection (HCV). GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The company's lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. In May 2009, the company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company's web site at www.globeimmune.com.

Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC; Department of Medicine, University of Arizona College of Medicine, Tucson, AZ; Center for Liver Diseases, University of Miami School of Medicine, Miami, FL; Department of Medicine, University of Colorado Denver, Aurora, CO; Scripps Clinic, La Jolla, CA; Maryland Digestive Disease Research, Laurel, MD; Department of Medicine and Surgery, Baylor College of Medicine, Houston, TX; St. Luke's Episcopal Hospital, Houston, TX; Alamo Medical Research, San Antonio, TX; South Denver Gastroenterology, Denver, CP; Center for Disease of the Liver and Pancreas, Swedish Medical Center, Englewood, CO; University of Hawaii, Honolulu, HI; Liver Institute of Virginia, Bon Secours Health System, Newport News, VA; Northwest Indiana Center for Clinical Research, Valparaiso, IN; Gastrointestinal Specialists of Georgia, Marietta, GA; QST Consultations, LTD, Allendale, MI; GlobeImmune, Inc., Louisville, CO; AIP Laboratories, Silver Spring, MD; University of Texas Southwestern Medical Center at Dallas, Dallas, TX; Columbia University College of Physicians & Surgeons, New York, NY; Saint Louis University, St. Louis, MO; Henry Ford Hospital, Detroit, MI.

4/27/10

Source
GlobeImmune, Inc. GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV. Press release. April 15, 2010.

References
IM Jacobson, JG McHutchison, TD Boyer, and others. GI-5005 therapeutic vaccine plus peg-IFN/ribavirin significantly improves virologic response and ALT normalization at end-of-treatment and improves SVR24 compared to peg-IFN/ribavirin in genotype-1 chronic HCV patients. 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria. April 14-18, 2010. (Abstract).

JG McHutchison, ZD Goodman, GT Everson, and others. GI-5005 therapeutic vaccine plus peg-IFN/ribavirin improves biopsy necro-inflammatory scores and ALT normalization at 48 weeks versus peg-IFN/ribavirin in genotype 1 chronic HCV patients. 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria. April 14-18, 2010. (Abstract).

JG McHutchison, AJ Thompson, IM Jacobson, and others. Pharmacogenomic analysis reveals improved virologic response in all IL-28b genotypes in naive genotype 1 chronic HCV patients treated with GI-5005 therapeutic vaccine plus peg-IFN/ribavirin. 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria. April 14-18, 2010. (Abstract).



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



EASL 2010 MAIN PAGE